<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24177" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Leiomyoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Florence</surname>
            <given-names>Ashley M.</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fatehi</surname>
            <given-names>Mary</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ashley Florence declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mary Fatehi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24177.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Leiomyomas, also known as fibroids, are a group of benign smooth muscle tumors commonly present in premenopausal women. These tumors are of monoclonal origin which arises from the smooth muscle of the uterus. This activity describes the evaluation and treatment of leiomyomas and explains the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the risk factors for developing leiomyoma.</p></list-item><list-item><p>Describe the hormone responsiveness of tumors in the pathophysiology of leiomyomas.</p></list-item><list-item><p>Explain the FIGO classification in the evaluation of leiomyomas.</p></list-item><list-item><p>Outline the imporatance of improving care coordination among the interprofessional team to enhance delivery of care for patients affected by leiomyoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24177&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24177">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24177.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Leiomyomas, also called fibroids, are the most common benign gynecological tumor in premenopausal women&#x000a0;<xref ref-type="bibr" rid="article-24177.r1">[1]</xref><xref ref-type="bibr" rid="article-24177.r2">[2]</xref>. The economic impact of fibroids is profound, affecting an estimated 11 million women <xref ref-type="bibr" rid="article-24177.r3">[3]</xref>&#x000a0;and costing approximately 34 billion dollars in the United States annually <xref ref-type="bibr" rid="article-24177.r4">[4]</xref>. This article presents the general approach to diagnosis, pathophysiology, histology, and treatment&#x000a0;of leiomyomas.</p>
      </sec>
      <sec id="article-24177.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Leiomyomas are comprised of monoclonal cells arising from the myometrium <xref ref-type="bibr" rid="article-24177.r5">[5]</xref>. Continued&#x000a0;research&#x000a0;to determine the&#x000a0;etiology of leiomyomas is ongoing. Several studies have&#x000a0;identified&#x000a0;specific gene mutations associated with fibroids&#x000a0;<xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.&#x000a0;Some mutations have been linked to defects in cell transformation&#x000a0;involving the RNA polymerase II transcriptional mediator subunit, MED12 <xref ref-type="bibr" rid="article-24177.r5">[5]</xref>.</p>
      </sec>
      <sec id="article-24177.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Leiomyomas are diagnosed in&#x000a0;close to 70% of white women and more than 80% of black women&#x000a0;by age 50, but the incidence of clinical symptoms&#x000a0;in&#x000a0;blacks is&#x000a0;double that found in&#x000a0;whites&#x000a0;<xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.&#x000a0; In addition to African descent, several factors are commonly associated with a higher risk of developing fibroids: early menarche, use of oral contraception before the age of 16 and an increase in body mass index. Conversely, the use of progestin-only contraceptives as well as multiparity decrease this risk <xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.</p>
      </sec>
      <sec id="article-24177.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Clinically, it is well established that leiomyomas are highly sensitive to the effects of steroid hormones. Leiomyomas have an increased expression of both estrogen and progesterone receptors when compared to normal myometrium <xref ref-type="bibr" rid="article-24177.r6">[6]</xref>. Studies indicate that ovarian steroids, estradiol, and progesterone, promote the growth of leiomyomas; and that the size of fibroids often decline after menopause when levels of those hormones fall <xref ref-type="bibr" rid="article-24177.r7">[7]</xref>.</p>
      </sec>
      <sec id="article-24177.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Leiomyomas are benign tumors&#x000a0;of monoclonal origin which arise from the smooth muscle of the uterus<xref ref-type="bibr" rid="article-24177.r2">[2]</xref><xref ref-type="bibr" rid="article-24177.r8">[8]</xref>. Leiomyomas are primarily composed of extracellular matrix and cells with a low mitotic index <xref ref-type="bibr" rid="article-24177.r7">[7]</xref><xref ref-type="bibr" rid="article-24177.r8">[8]</xref>. They are encapsulated with a pseudocapsule composed of areolar tissue <xref ref-type="bibr" rid="article-24177.r8">[8]</xref>.</p>
      </sec>
      <sec id="article-24177.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical presentation of fibroids is variable, ranging from asymptomatic patients to those with recurrent, progressive symptoms that adversely affect a woman&#x02019;s daily activities. The most common presenting symptoms are pain, pressure, and abnormal vaginal bleeding <xref ref-type="bibr" rid="article-24177.r7">[7]</xref>. Important determinants of symptoms are the location, size, and the number of leiomyomas&#x000a0;<xref ref-type="bibr" rid="article-24177.r1">[1]</xref>. Physical examination usually confirms an enlarged, irregularly-shaped uterus <xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.</p>
      </sec>
      <sec id="article-24177.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosis of uterine leiomyomas is generally made by comprehensive physical examination and clinical history. On physical exam, the most common finding is an enlarged uterus that is often irregular in shape. Confirmation of&#x000a0;clinical diagnosis is most easily&#x000a0;accomplished with ultrasonography.&#x000a0;A pelvic sonogram&#x000a0;is a cost-effective method that allows for rapid diagnosis <xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.</p>
        <p>Further imaging, such as magnetic resonance imaging (MRI), can be useful for determining the extent of vascularization or degeneration of the leiomyomas. MRI can also better define the relationship of the leiomyomas to the serosal and mucosal surfaces. The proximity to these surfaces often dictates the type of intervention recommended <xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.</p>
        <p>The International Federation of Gynecology and Obstetrics (FIGO) has developed a classification system that allows for the determination of the extent of invasion into the endometrial cavity. The FIGO scale ranges from 0 to 8, with the lower number indicating closer proximity to the endometrium<xref ref-type="bibr" rid="article-24177.r2">[2]</xref><xref ref-type="bibr" rid="article-24177.r9">[9]</xref>.</p>
        <p>If bleeding is the predominant symptom and there is a concern for anemia or other sequelae of recurrent blood loss, a complete blood count (CBC) is indicated. Further evaluation of blood work should include a thyroid-stimulating hormone level to rule out thyroid disease as the cause of abnormal bleeding if the index of suspicion is low for leiomyomata&#x000a0;as the etiology&#x000a0;<xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.</p>
        <p>At this time, there is no recommendation for surveillance imaging. While the growth of the leiomyoma can be surveyed, there is no current basis for a set time interval or current guidelines on how the growth should be monitored. Interval reassessment is usually based on a change in clinical symptoms <xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.</p>
      </sec>
      <sec id="article-24177.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The economic impact on the United States by the cost of care for symptomatic leiomyomas is excessive&#x000a0;<xref ref-type="bibr" rid="article-24177.r1">[1]</xref>. Effective treatment is necessary to not only reduce the detrimental effects they pose on a women&#x02019;s daily function, but also to mitigate the economic burden on healthcare <xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.</p>
        <p>The patient&#x02019;s age and reproductive goals direct the modality and goals of treatment. Treatment options include both medical and surgical intervention <xref ref-type="bibr" rid="article-24177.r1">[1]</xref>. Treatment goals should fulfill three objectives:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Relieve&#x000a0;bothersome signs and symptoms</p>
          </list-item>
          <list-item>
            <p>Reduce&#x000a0;the leiomyoma size&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Maintain or improve a woman&#x02019;s fertility if desired&#x000a0;<xref ref-type="bibr" rid="article-24177.r1">[1]</xref>.</p>
          </list-item>
        </list>
        <p>Medical management is often the initial intervention for symptomatic fibroids and includes hormonal therapy, nonsteroidal anti-inflammatory drugs (NSAIDs) and/or modulation of the hypothalamic-pituitary axis. The major&#x000a0;drawback of medical management is the limited duration of use. Many of the medical management options are only able to be used for a short duration, and after the cessation of treatment,&#x000a0;symptoms reoccur,&#x000a0;and the fibroids often continue to grow&#x000a0;<xref ref-type="bibr" rid="article-24177.r1">[1]</xref>.</p>
        <p>Hormonal options for treatment include combination oral contraceptives, single agent progesterone suppression or GnRH agonists. Systemic hormonal therapy is primarily used to control menorrhagia caused by fibroids,&#x000a0;rarely&#x000a0;impacts the size of fibroids and does not improve fertility.&#x000a0; Additionally, increased complications are associated with long-term treatment&#x000a0;using exogenous hormones; therefore, they are generally only used for short durations&#x000a0;<xref ref-type="bibr" rid="article-24177.r1">[1]</xref>. Gonadotropin-releasing hormone (GnRH) agonists&#x000a0;inhibit&#x000a0;production of endogenous progesterone and estrogen.&#x000a0; The overall&#x000a0;effects are similar to those of menopause, thus resulting in amenorrhea and subsequent decrease in uterine volume&#x000a0;<xref ref-type="bibr" rid="article-24177.r1">[1]</xref><xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.&#x000a0; However, these effects are limited to the duration of use.</p>
        <p>Intrauterine devices that release levonorgestrel act locally to achieve results similar to systemic progesterone suppression, resulting in decreased menstrual bleeding and improved quality of life&#x000a0;<xref ref-type="bibr" rid="article-24177.r2">[2]</xref>. While they provide symptomatic relief, they do not have any long-term effect on decreasing the overall size of the uterine fibroids; thus providing little help with bulk symptoms <xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.</p>
        <p>Non-hormonal options involve NSAIDs and tranexamic acid. Tranexamic acid is a derivative of the amino acid, lysine.&#x000a0; This medication is&#x000a0;a reversible inhibitor of lysine receptor sites&#x000a0;on plasminogen&#x000a0;that, when bound, prevent&#x000a0;fibrin degradation&#x000a0;and&#x000a0;functionally stabilize clot&#x000a0;formation&#x000a0;<xref ref-type="bibr" rid="article-24177.r1">[1]</xref>. There are few side effects associated with tranexamic acid. The most common&#x000a0;is gastrointestinal upset, while the most feared is venous thromboembolism<xref ref-type="bibr" rid="article-24177.r1">[1]</xref>&#x000a0;<xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.&#x000a0;Clinical&#x000a0;studies have found no significant evidence for the&#x000a0;theoretical increased risk of venous thromboembolism&#x000a0;from use of tranexamic acid&#x000a0;<xref ref-type="bibr" rid="article-24177.r1">[1]</xref>. However, due to potential increased thrombotic risk with hormonal therapy, tranexamic acid is usually prescribed as a single agent therapy&#x000a0;<xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.</p>
        <p>NSAIDs have been useful for reducing menstrual blood loss <xref ref-type="bibr" rid="article-24177.r1">[1]</xref>. NSAIDs decrease the endometrial prostaglandins, which subsequently inhibit aberrant vascularization and neovascularization <xref ref-type="bibr" rid="article-24177.r1">[1]</xref><xref ref-type="bibr" rid="article-24177.r2">[2]</xref>. While NSAIDs&#x000a0;are effective for decreasing menstrual flow, they are inferior to tranexamic acid and levonorgestrel-releasing IUDs&#x000a0;<xref ref-type="bibr" rid="article-24177.r2">[2]</xref>&#x000a0;<xref ref-type="bibr" rid="article-24177.r10">[10]</xref>.</p>
        <p>Surgical intervention remains the&#x000a0;most successful&#x000a0;treatment for leiomyomas. Endometrial ablation is hysteroscopic destruction of the full-thickness endometrium, but this treatment precludes future endometrial assessment and requires permanent contraception.&#x000a0; Uterine artery embolization reduces blood flow to individual fibroids to reduce growth and mitigate symptoms.&#x000a0; Successful myomectomy (surgical removal of fibroids only) enables future fertility while reducing size and symptoms from fibroids; however, many women will require additional&#x000a0;subsequent procedures for recurrent symptomatic fibroids.&#x000a0; Hysterectomy is the only treatment that provides definitive therapy&#x000a0;<xref ref-type="bibr" rid="article-24177.r2">[2]</xref>. There are various methods of performing a hysterectomy, the choice&#x000a0;of which is highly dependent on the patients&#x02019; history, physical findings and the individual surgeon's&#x000a0;training and experience&#x000a0;<xref ref-type="bibr" rid="article-24177.r2">[2]</xref>.</p>
      </sec>
      <sec id="article-24177.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for uterine leiomyomas includes both benign and malignant diseases that cause uterine enlargement, bleeding or pelvic pain. The most common diagnoses to consider are adenomyosis, endometriosis, pregnancy, leiomyosarcoma, endometrial carcinoma and uterine carcinosarcoma <xref ref-type="bibr" rid="article-24177.r11">[11]</xref>. While these cancers are rare causes of symptoms consistent with leiomyomas, the clinician must maintain a high index of suspicion during evaluation.</p>
      </sec>
      <sec id="article-24177.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of uterine fibroids varies extensively&#x000a0;for individual patients. Many patients have an excellent prognosis and remain asymptomatic for many years or indefinitely. Whereas, others will fail medical management and depending on their desire for future fertility, may&#x000a0;experience recurrent fibroids requiring multiple surgeries.&#x000a0;</p>
      </sec>
      <sec id="article-24177.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Chronic pelvic pain</p>
          </list-item>
          <list-item>
            <p>Heavy menstrual bleeding, which can lead to anemia</p>
          </list-item>
          <list-item>
            <p>Poor pregnancy outcomes&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Infertility&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Constipation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Urinary tract infections or urinary incontinence</p>
          </list-item>
          <list-item>
            <p>Torsion&#x000a0;of a pedunculated fibroid&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Degeneration&#x000a0;with or without infection</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24177.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <list list-type="bullet">
          <list-item>
            <p>Leiomyomas are benign and rarely become cancer</p>
          </list-item>
          <list-item>
            <p>Extremely common among women&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Genetics may play a role in your chance of developing them</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24177.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Considering the high prevalence and incidence of uterine leiomyomas, the need for full integration of care among health care professionals is essential. To expand our knowledge of leiomyomas, we need further research to identify predisposing genetic factors for potential use to better target&#x000a0;preventive care. Current randomized trials have shown progress in the treatment of symptoms to improve quality of life. One of the most recent phase three trials found the use of ulipristal acetate, an oral progesterone receptor modulator significantly improves bleeding among women with symptomatic leiomyomas <xref ref-type="bibr" rid="article-24177.r12">[12]</xref>. While this is a step in the right direction, the need for further understanding of the&#x000a0;pathophysiology of leiomyomas is essential for&#x000a0;optimal care of this large population of patients.</p>
      </sec>
      <sec id="article-24177.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24177&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24177">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/womens-health/leiomyoma-uterine-fibroids/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24177">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24177/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24177">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24177.s16">
        <title>References</title>
        <ref id="article-24177.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashani</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Centini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morelli</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Petraglia</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Role of Medical Management for Uterine Leiomyomas.</article-title>
            <source>Best Pract Res Clin Obstet Gynaecol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>34</volume>
            <fpage>85</fpage>
            <page-range>85-103</page-range>
            <pub-id pub-id-type="pmid">26796059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24177.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Laughlin-Tommaso</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Catherino</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Lalitkumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vollenhoven</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Uterine fibroids.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2016</year>
            <month>Jun</month>
            <day>23</day>
            <volume>2</volume>
            <fpage>16043</fpage>
            <pub-id pub-id-type="pmid">27335259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24177.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marsh</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Al-Hendy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kappus</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Galitsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Kerolous</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women.</article-title>
            <source>J Womens Health (Larchmt)</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>1359</fpage>
            <page-range>1359-1367</page-range>
            <pub-id pub-id-type="pmid">30230950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24177.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cardozo</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Banks</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Henne</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Stegmann</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Segars</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>The estimated annual cost of uterine leiomyomata in the United States.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>206</volume>
            <issue>3</issue>
            <fpage>211.e1</fpage>
            <page-range>211.e1-9</page-range>
            <pub-id pub-id-type="pmid">22244472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24177.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kudo-Asabe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nanjo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ikemura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukayama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>MED12 is frequently mutated in ovarian and other adnexal leiomyomas.</article-title>
            <source>Hum Pathol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>81</volume>
            <fpage>89</fpage>
            <page-range>89-95</page-range>
            <pub-id pub-id-type="pmid">29944972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24177.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doherty</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mutlu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Uterine fibroids: clinical manifestations and contemporary management.</article-title>
            <source>Reprod Sci</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>1067</fpage>
            <page-range>1067-92</page-range>
            <pub-id pub-id-type="pmid">24819877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24177.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghosh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Naftalin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Imrie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hoo</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Natural History of Uterine Fibroids: A Radiological Perspective.</article-title>
            <source>Curr Obstet Gynecol Rep</source>
            <year>2018</year>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>117</fpage>
            <page-range>117-121</page-range>
            <pub-id pub-id-type="pmid">30101039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24177.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holdsworth-Carson</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Zaitseva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vollenhoven</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Clonality of smooth muscle and fibroblast cell populations isolated from human fibroid and myometrial tissues.</article-title>
            <source>Mol Hum Reprod</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>250</fpage>
            <page-range>250-9</page-range>
            <pub-id pub-id-type="pmid">24243625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24177.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munro</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Critchley</surname>
                <given-names>HO</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>IS</given-names>
              </name>
              <collab>FIGO Menstrual Disorders Working Group</collab>
            </person-group>
            <article-title>The FIGO classification of causes of abnormal uterine bleeding in the reproductive years.</article-title>
            <source>Fertil Steril</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>95</volume>
            <issue>7</issue>
            <fpage>2204</fpage>
            <page-range>2204-8, 2208.e1-3</page-range>
            <pub-id pub-id-type="pmid">21496802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24177.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lethaby</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Duckitt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Farquhar</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2013</year>
            <month>Jan</month>
            <day>31</day>
            <issue>1</issue>
            <fpage>CD000400</fpage>
            <pub-id pub-id-type="pmid">23440779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24177.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleischer</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Millis</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Differential diagnosis of pelvic masses by gray scale sonography.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>1978</year>
            <month>Sep</month>
            <volume>131</volume>
            <issue>3</issue>
            <fpage>469</fpage>
            <page-range>469-76</page-range>
            <pub-id pub-id-type="pmid">98992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24177.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simon</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Catherino</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Segars</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Blakesley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sniukiene</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Al-Hendy</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>131</volume>
            <issue>3</issue>
            <fpage>431</fpage>
            <page-range>431-439</page-range>
            <pub-id pub-id-type="pmid">29420395</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
